Authors : Gaurav Patel

Volume/Issue : Volume 11 - 2026, Issue 2 - February

Google Scholar : https://tinyurl.com/4ycts6tt

Scribd : https://tinyurl.com/4j5ekj68

DOI : https://doi.org/10.38124/ijisrt/26feb1035

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Microfluidic technologies have emerged as powerful tools in pharmaceutical sciences, offering precise control over fluid handling, mixing, and mass transfer at the microscale. These unique characteristics have enabled significant advances in controlled pharmaceutical formulation and drug screening, addressing key limitations of conventional bulk-scale methods, such as poor reproducibility, high material consumption, and limited physiological relevance. This review provides a comprehensive overview of recent progress in microfluidics for pharmaceutical applications, with a focus on formulation control, nanocarrier and advanced drug delivery system fabrication, controlled release, and stability enhancement. The role of microfluidic platforms in high-throughput and physiologically relevant drug screening, including cell-based and organon-chip models, is critically discussed. Furthermore, the integration of microfluidics with emerging technologies such as automation, artificial intelligence, digital microfluidics, and advanced analytical tools is highlighted as a driver of datadriven and continuous pharmaceutical development. Key challenges related to scalability, standardization, regulatory acceptance, and ethical considerations are also examined. Finally, future perspectives emphasize the growing translational potential of microfluidics in continuous manufacturing, personalized medicine, and precision therapeutics. Overall, this review underscores the transformative impact of microfluidic technologies on modern pharmaceutical formulation and drug screening, positioning them as integral components of next-generation drug development pipelines.

Keywords : Microfluidics; Pharmaceutical Formulation; Drug Screening; Nanocarriers; Controlled Drug Release; Advanced Drug Delivery Systems; Lab-On-A-Chip; Organ-On-Chip; Continuous Manufacturing; Precision Medicine.

References :

1. K. F. Lei, ‘Introduction: The Origin, Current Status, and Future of Microfluidics’, in Microfluidics: Fundamentals, Devices and Applications, 2018. doi: 10.1002/9783527800643.ch1.
2. G. M. Whitesides, ‘The origins and the future of microfluidics’, 2006. doi: 10.1038/nature05058.
3. D. Gohel, ‘Hospital Microbiome and Infection Control’, International Journal of Scientific Research in Engineering and Management (IJSREM), vol. 10, no. 01, pp. 1–7, 2026.
4. D. Gohel, ‘Rapid Molecular Diagnostics in Clinical Trials and Hospital Infection Management’, INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 4, no. 01, pp. 719–733, 2026.
5. D. Gohel, ‘Vaccine and Immunotherapy Trials: Building on the Rapid Advancements  from the COVID-19 Pandemic’, International Journal of Scientific Research in Engineering and Management (IJSREM), vol. 9, no. 11, pp. 1–8, 2026.
6. S. Patel, C. Shukla, G. Patel, and G. Stagni, ‘Pharmacokinetics of amitriptyline in rabbit skin and plasma following iontophoretic administrations’, Drug Dev. Ind. Pharm., vol. 36, no. 4, pp. 379–384, 2010.
7. D. Gohel and G. Patel, ‘THE TRANSFORMATIVE ROLE OF AI IN CLINICAL TRIAL MANAGEMENT: FROM PATIENT RECRUITMENT TO REAL-TIME MONITORING’, Sciences, vol. 15, no. 1, pp. 276–299.
8. G. M. Whitesides and A. D. Stroock, ‘Flexible methods for microfluidics’, Phys. Today, vol. 54, no. 6, 2001, doi: 10.1063/1.1387591.
9. H. A. Stone, A. D. Stroock, and A. Ajdari, ‘Engineering flows in small devices: Microfluidics toward a lab-on-a-chip’, Annu. Rev. Fluid Mech., vol. 36, 2004, doi: 10.1146/annurev.fluid.36.050802.122124.
10. K. Thejomoorthy et al., ‘Simultaneous Quantification of Luteolin and Curcumin in Herbal Supplements Using RP-HPLC for Addressing Nutritional Deficiencies.’, Frontiers in Health Informatics, vol. 13, no. 8, 2024.
11. T. T. H. Yen, D. T. Linh, and P. T. Minh Hue, ‘The Application of Microfluidics in Preparing Nano Drug Delivery Systems’, VNU Journal of Science: Medical and Pharmaceutical Sciences, vol. 35, no. 1, 2019, doi: 10.25073/2588-1132/vnumps.4150.
12. R. Karnik et al., ‘Microfluidic platform for controlled synthesis of polymeric nanoparticles’, Nano Lett., vol. 8, no. 9, 2008, doi: 10.1021/nl801736q.
13. N. R. Soundaryashree et al., ‘Development and validation of rp-hplc method for quantification of bamifylline in pharmaceutical formulations using analytical quality by design (aqbd) principles’, Advanced Journal of Chemistry. Section A, pp. 2076–2097, 2025.
14. G. Nunziata, A. Borroni, and F. Rossi, ‘Advanced microfluidic strategies for core-shell nanoparticles: the next-generation of polymeric and lipid-based drug nanocarriers’, 2025. doi: 10.1016/j.ceja.2025.100759.
15. R. R. Hood and D. L. Devoe, ‘High-Throughput Continuous Flow Production of Nanoscale Liposomes by Microfluidic Vertical Flow Focusing’, Small, vol. 11, no. 43, 2015, doi: 10.1002/smll.201501345.
16. D. Gohel, ‘Antimicrobial Resistance (AMR) Trials: Clinical Trials are Essential for Testing New Approaches to Combat the Rise of AMR’, INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 3, no. 12, pp. 2836–2848, 2026.
17. D. Gohel, ‘IMMUNOTHERAPY AND CANCER: CLINICAL RESEARCH EXPLORING THE ROLE OF THE MICROBIOME AND THE IMMUNE SYSTEM IN CANCER TREATMENT, INCLUDING THE POTENTIAL FOR MICROBIAL AGENTS IN CANCER VACCINES’, International Research Journal of Modernization in Engineering Technology and Science, vol. 7, no. 10, pp. 3800–3811, 2025.
18. G. P. Dhavalkumar Gohel, ‘THE TRANSFORMATIVE ROLE OF AI IN CLINICAL TRIAL MANAGEMENT: FROM PATIENT RECRUITMENT TO REAL-TIME MONITORING’, World J. Pharm. Pharm. Sci., vol. 15, no. 01, pp. 276–299, 2026.
19. G. Tiwari et al., ‘Design and optimization of PLGA-based gemcitabine nanocapsule for enhanced pancreatic cancer efficacy’, Invest. New Drugs, vol. 43, no. 4, pp. 800–819, 2025.
20. K. S. Samanthula et al., ‘Physiological, In-vitro, and Analytical Studies of Cellular Oxidative Stress for Evaluation of Antioxidant Pharmacological Effects of Natural Polysaccharide in Fast Dissolving Tablet Formulations.’, Frontiers in Health Informatics, vol. 13, no. 5, 2024.
21. A. Ebrahimiverkiani, M. Ebrahimi Varkiani, M. Jadid Tavaf, S. M. Naghib, and N. Rabiee, ‘Microfluidic-engineered polymeric nanocarriers for targeted drug delivery in liver cancer therapy: part I principles’, 2025. doi: 10.1080/17425247.2025.2587902.
22. G. V. Grigorev, A. V. Lebedev, X. Wang, X. Qian, G. V. Maksimov, and L. Lin, ‘Advances in Microfluidics for Single Red Blood Cell Analysis’, 2023. doi: 10.3390/bios13010117.
23. P. S. Dittrich and A. Manz, ‘Lab-on-a-chip: Microfluidics in drug discovery’, 2006. doi: 10.1038/nrd1985.
24. A. Skardal, T. Shupe, and A. Atala, ‘Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling’, 2016. doi: 10.1016/j.drudis.2016.07.003.
25. C. Li, J. Zhai, and Y. Jia, ‘Digital Microfluidics with an On-Chip Drug Dispenser for Single or Combinational Drug Screening’, in Methods in Molecular Biology, vol. 2679, 2023. doi: 10.1007/978-1-0716-3271-0_3.
26. F. Eduati et al., ‘A microfluidics platform for combinatorial drug screening on cancer biopsies’, Nat. Commun., vol. 9, no. 1, 2018, doi: 10.1038/s41467-018-04919-w.
27. L. Shang, Y. Cheng, and Y. Zhao, ‘Emerging Droplet Microfluidics’, 2017. doi: 10.1021/acs.chemrev.6b00848.
28. J. Zhou, J. Dong, H. Hou, L. Huang, and J. Li, ‘High-throughput microfluidic systems accelerated by artificial intelligence for biomedical applications’, 2024. doi: 10.1039/d3lc01012k.
29. J. Rajawat, I. Vohra, H. A. Mir, D. Gohel, and R. Begum, ‘Effect of oxidative stress and involvement of poly (ADP‐ribose) polymerase (PARP) in Dictyostelium discoideum development’, FEBS J., vol. 274, no. 21, pp. 5611–5618, 2007.
30. B. Pardiwalla et al., ‘Convalescent plasma to limit coronavirus associated complications: a proof of concept phase-2 clinical study at a designated COVID-19 hospital in Mumbai city’, J Curr Med Res Opin, vol. 4, no. 05, pp. 940–949, 2021.
31. A. Bezelya, B. Küçüktürkmen, and A. Bozkır, ‘Microfluidic Devices for Precision Nanoparticle Production’, 2023. doi: 10.3390/micro3040058.
32. G. Y. Ahn et al., ‘Continuous production of lipid nanoparticles by multiple-splitting in microfluidic devices with chaotic microfibrous channels’, Colloids Surf. B Biointerfaces, vol. 224, 2023, doi: 10.1016/j.colsurfb.2023.113212.
33. A. Ofner et al., ‘High-Throughput Step Emulsification for the Production of Functional Materials Using a Glass Microfluidic Device’, Macromol. Chem. Phys., vol. 218, no. 2, 2017, doi: 10.1002/macp.201600472.
34. S. Bonaccorsi, ‘Organ-on-a-chip Technology Roadmap: Regulatory Framework, Industry Adoption, Key Players, Technology Transfer, Validation, and Ethical Considerations’, in Lab-on-a-chip Devices for Advanced Biomedicines, 2024. doi: 10.1039/9781837673476-00461.
35. J. Berthier and K. A. Brakke, The Physics of Microdroplets. 2012. doi: 10.1002/9781118401323.
36. D. J. Beebe, G. A. Mensing, and G. M. Walker, ‘Physics and applications of microfluidics in biology’, 2002. doi: 10.1146/annurev.bioeng.4.112601.125916.
37. K. F. Jensen, ‘Flow chemistry—Microreaction technology comes of age’, AIChE Journal, vol. 63, no. 3, 2017, doi: 10.1002/aic.15642.